This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
You can help expand this article with text translated from the corresponding article in Dutch. (July 2022) Click [show] for important translation instructions.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consider adding a topic to this template: there are already 373 articles in the main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Dutch Wikipedia article at [[:nl:Exact name of the Dutch article]]; see its history for attribution.
You may also add the template {{Translated page|nl|Exact name of Dutch article}} to the talk page.
For more guidance, see Wikipedia:Translation.
You can help expand this article with text translated from the corresponding article in German. (March 2020) Click [show] for important translation instructions.
View a machine-translated version of the German article.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consider adding a topic to this template: there are already 9,139 articles in the main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing German Wikipedia article at [[:de:CureVac]]; see its history for attribution.
You may also add the template {{Translated|de|CureVac}} to the talk page.
For more guidance, see Wikipedia:Translation.
This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view.(July 2022) (Learn how and when to remove this message)
(Learn how and when to remove this message)
CureVac N.V.
Company type
Public
Traded as
Nasdaq: CVAC
Industry
Biotechnology
Founded
2000; 24 years ago (2000)
Founders
Ingmar Hoerr,[1] Steve Pascolo, Florian von der Muelbe, Günther Jung and Hans-Georg Rammensee
Headquarters
Tübingen, Germany
Key people
Franz-Werner Haas (CEO)
Total equity
€1.40 billion (October 2017)
Number of employees
< 700[2]
Website
www.curevac.com
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018.[2]
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus.[3] Clinical trials for the CureVac COVID-19 Vaccine (CVnCoV) began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company.[3][4][5] In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy.[6] In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology.[7][8]
The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline,[9][10] Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative,[11] and the government of Germany.[12]
^"CureVac Announces New Management Structure" (Press release). Curevac. Archived from the original on 21 June 2018. Retrieved 21 June 2018.
^ ab"Company Information". Curevac. Archived from the original on 27 November 2020. Retrieved 18 December 2020.
^ abMiller, Joe; Chazan, Guy; Cookson, Clive (15 June 2020). "Berlin to buy stake in Covid-19 vaccine player CureVac". Financial Times. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
^Sovereign (15 June 2020). "German Federal Government invests 300 Million Euros in CureVac". CureVac. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
^"German government invests in the development of a vaccine". Website of the Federal Government | Bundesregierung. 17 June 2020. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
^Cohen, John (18 June 2021). "What went wrong with CureVac's highly anticipated new mRNA vaccine for COVID-19?". Science.org. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
^Szymanska, Zuzanna; Burger, Ludwig (12 October 2021). "CureVac drops COVID-19 vaccine, pins hope on next-generation shots". Reuters. Retrieved 14 August 2023.
^Solomon, Erika; Kuchler, Hannah (12 October 2021). "CureVac drops Covid vaccine to focus on new jab with GSK". Financial Times. Archived from the original on 14 August 2023. Retrieved 14 August 2023.
^Carroll, John (18 October 2017). "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines". endpts.com. Archived from the original on 7 April 2020. Retrieved 8 May 2018.
^Aripaka, Pushkala; Schuetze, Arno (19 July 2020). "GSK buys 10% of CureVac in vaccine tech deal". Reuters. Archived from the original on 14 August 2020. Retrieved 21 July 2020.
^"CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard". 10 September 2015. Archived from the original on 23 May 2020. Retrieved 3 December 2015.
^Cite error: The named reference dw was invoked but never defined (see the help page).
Tesla and CureVac filed a joint patent on the technology. In August, Musk reviewed the project with Curevac while in Germany. By 2017, CureVac had received...
including Deutsche Post, Deutsche Telekom, Commerzbank, Lufthansa, and CureVac. In 2013, KfW agreed to help establish a Portuguese financial institution...
(€955 million). In July 2020, GSK acquired a 10% stake in German biotech company CureVac. In March 2018, GSK announced that it has reached an agreement with Novartis...
patent on Moderna's mRNA vaccine technology, are ongoing. DNA vaccine CureVac "Moderna, Inc., 2023, Form 10-K Annual Report". U.S. Securities and Exchange...
or the Walvax COVID-19 vaccine used in Indonesia (and the now abandoned CureVac vaccine candidate, as well), do not have such requirements. In RNA therapeutics...
concerning the use of RNA and is a founder of the German biotechnology company CureVac. He created the initial technology used in RNA vaccines and has reportedly...
Oxford-AstraZeneca at €1.78; Johnson & Johnson at $8.50, Sanofi-GSK at €7.56, CureVac at €10, and Moderna at $18. In the same month, Israel ordered 8 million...
Retrieved February 3, 2020. "CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019". CureVac AG. January 31, 2020. Archived...
February 2019, CEPI announced funding of US$34 million to the German-based CureVac biopharmaceutical company to develop an "RNA Printer prototype", that CEPI...
Zeiss AG Health care Medical equipment Oberkochen 1846 Optical systems CureVac Health care Vaccine Tübingen 2000 Biotechnology Celesio Health care Pharmaceuticals...
still face major delivery hurdles. BioNTech, Moderna Therapeutics and CureVac focus on delivery of mRNA payloads, which are necessarily non-viral delivery...
"Nisovo Vrelo", the deepest part of the canyon. Further is the bottom of Curevac mountain that reaches 1,650 metres (5,410 ft). In 2005 and 2009, the European...
mRNA Covid 19 vaccines that Acuitas developed with Pfizer/BioNTech and CureVac. The Pfizer/BioNTech COVID-19 mRNA vaccine BNT162b2 relies on an LNP delivery...